Artificial Chiral Interfaces against Amyloid-β Peptide Aggregation: Research Progress and Challenges

Area of Science:

• Nanomedicine
• Neurodegenerative Disorders
• Biochemistry

Background:

• Alzheimer's disease (AD) involves amyloid-beta (Aβ) aggregation, impacting patient quality of life and societal burden.
• Engineered nanostructures are emerging as potential inhibitors of Aβ aggregation.
• The role of chirality in nanostructure-based Aβ inhibition remains underexplored.

Purpose of the Study:

• To review experimental and theoretical findings on artificial chiral nanostructures as Aβ amyloid inhibitors.
• To elucidate the molecular mechanisms by which chiral nanointerfaces affect Aβ recognition and aggregation.
• To highlight the potential of chiral nanostructures in developing novel anti-amyloidosis drugs.

Main Methods:

• Review of recent experimental studies on chiral nanostructures and Aβ aggregation.
• Analysis of theoretical models investigating chiral effects at the nano-bio interface.
• Synthesis of current knowledge on nanostructure surface properties (morphology, charge, hydrophobicity) and their influence on Aβ adsorption.

Main Results:

• Chirality has been largely overlooked in the design of Aβ aggregation inhibitors.
• Nanostructural surface properties influence Aβ peptide adsorption and subsequent aggregation.
• Emerging evidence suggests chiral nanostructures can modulate Aβ recognition and aggregation pathways.

Conclusions:

• Chiral nanostructures represent a novel frontier in nanomedicine for targeting Alzheimer's disease.
• Further research into the molecular mechanisms of chiral nano-Aβ interactions is essential.
• Development of chiral inhibitor drugs holds significant therapeutic potential against Aβ fibrillation.